Osteoarthritis of the Knee
Conditions
Keywords
Osteoarthritis, OA, Arthritis pain
Brief summary
The primary purpose of the study is to evaluate the change from baseline after 4 weeks of topical administration of TV-45070 (4% and 8% ointment) compared with placebo for the relief of symptoms of primary OA affecting a single knee
Interventions
DRUGTV-45070
TV-45070 ointment administered twice a day (morning and evening) to target knee. Participants were provided with a laminated instruction sheet including pictures that both described and illustrated how the ointment was to be spread over the entire knee anteriorly, medially, and laterally in a thin layer that fully covered the area. The ointment was gently massaged into the skin.
DRUGPlacebo
Placebo ointment matching active intervention administered twice a day (morning and evening) to target knee. Participants were provided with a laminated instruction sheet including pictures that both described and illustrated how the ointment was to be spread over the entire knee anteriorly, medially, and laterally in a thin layer that fully covered the area. The ointment was gently massaged into the skin.
Sponsors
Teva Branded Pharmaceutical Products R&D, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
40 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Patient is between 40 and 85 years of age, Patient has primary OA in a single knee (target knee) confirmed by American College of Rheumatology criteria. * For patients taking non-steroidal anti-inflammatory drugs (NSAIDs) or other analgesics at the time of the screening visit, * Patient has visual analog scale (VAS) pain scores with acceptable ranges as determined by the investigator during screening * Except for OA, patient is judged by the investigator to be medically healthy and able to participate in the study. * Other criteria apply, please contact the investigator for additional information
Exclusion criteria
* Patient has secondary or inflammatory arthritis of the knee such as psoriasis, rheumatoid arthritis (RA), gout, other primary bone disease, or acute trauma. * Patient has symptomatic chondrocalcinosis * Patient has a history of fibromyalgia. * Patient has any painful or disabling conditions that in the opinion of the investigator may confound assessment of pain scoring. * Patient has uncontrolled cardiac, renal, hepatic or other systemic disorders that in the opinion of the investigator may jeopardize the patient. * Patient has significant edema or skin disorder (including sores, rashes, or ulcers) at the target knee and surrounding area. * Patient has a history of total or partial knee replacement in either leg. * Patient had a major reconstructive knee surgery or arthroscopy of the target knee within 6 months before the screening visit. * Patient is unable or unwilling to discontinue opioid and/or other prescription analgesics for control of OA pain. * Patient is intolerant to study drug, its excipients, and/or acetaminophen. * Patient uses any over the counter oral medications such as glucosamine or chondroitin sulfate products, unless the patient has been receiving the medication for ≥3 months at the time of the screening visit and maintains the medication as stable therapy for the duration of the study. * Other criteria apply, please contact the investigator for additional information
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline to Last 5 Days of Treatment in the Average Evening Pain Intensity In the Target Knee When Walking on a Flat Surface Using a Mixed Model for Repeated Measures (MMRM) | Baseline (day -5 to day -1), Last 5 days of treatment (day 24 to day 28) | The Western Ontario and McMasters Universities Arthritis Index \[WOMAC\] is a widely used, validated, patient-reported questionnaire used to assess pain, stiffness, and physical function in patients with OA of the knee. It consists of 24 items separated into 3 domains (pain \[5 items\], stiffness \[2 items\], and physical function \[17 items\]). WOMAC Question 1 is the first question in the pain domain and asks patients to rate their pain in the target knee while walking on a flat surface. The possible score for each item ranges from 0 (no pain) to 100 mm (worst pain). Participants record their response to WOMAC Question 1 in the study diary based on average pain upon walking since the last assessment or over the past 12 hours. Negative change from baseline scores indicate improvement in pain. MMRM includes week, treatment, study center, and treatment by week interaction as fixed factors; baseline average evening WOMAC Question 1 score as a covariate; and patient as a random factor. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline to Last 5 Days of Treatment in the Average Morning Pain Intensity In the Target Knee When Walking on a Flat Surface Using a Mixed Model for Repeated Measures (MMRM) | Baseline (day -5 to day -1), Last 5 days of treatment (day 24 to day 28) | The Western Ontario and McMasters Universities Arthritis Index \[WOMAC\] is a widely used, validated, patient-reported questionnaire used to assess pain, stiffness, and physical function in patients with OA of the knee. It consists of 24 items separated into 3 domains (pain \[5 items\], stiffness \[2 items\], and physical function \[17 items\]). The possible score for each item ranges from 0 (no pain) to 100 mm (worst pain). WOMAC Question 1 is the first question in the pain domain and asks patients to rate their pain in the target knee while walking on a flat surface. Participants record their response to WOMAC Question 1 in the study diary based on average pain upon walking since the last assessment or over the past 12 hours. Negative change from baseline scores indicate improvement in pain. MMRM includes week, treatment, study center, and treatment by week interaction as fixed factors; baseline average morning WOMAC Question 1 score as a covariate; and patient as a random factor. |
| Change From Baseline (Randomization Visit) to the Week 4 Visit in the WOMAC Physical Function Subscale Score for the Target Knee Using a Mixed Model for Repeated Measures | Baseline (day 1, predose), Treatment: Week 4 (day 29) | The seventeen items in the WOMAC physical function subscale cover stair use, rising from sitting, standing, bending, walking, getting in / out of a car, shopping, putting on / taking off socks, rising from bed, lying in bed, getting in / out of bath, sitting, getting on / off toilet, heavy household duties, light household duties. WOMAC physical function subscale score is calculated as the sum of the 17-item physical function subscale scores (WOMAC) for a total range of 0 (no pain) to 1700 (worst pain on all 17 items). Negative change from baseline scores indicate improvement in pain. MMRM includes week, treatment, study center, and treatment by week interaction as fixed factors; baseline physical function WOMAC scores for the 17-item subscale as a covariate; and patient as a random factor. |
| Change From Baseline (Randomization Visit) to the Week 4 Visit in the WOMAC Stiffness Subscale Score for the Target Knee Using a Mixed Model for Repeated Measures | Baseline (day 1, predose), Treatment: Week 4 (day 29) | The two items in the WOMAC stiffness subscale cover stiffness after first waking and later in the day. WOMAC stiffness subscale score is calculated as the sum of the 2-item stiffness subscale scores (WOMAC) for a total range of 0 (no stiffness) to 200 (worst stiffness on both items). Negative change from baseline scores indicate improvement in stiffness. MMRM includes week, treatment, study center, and treatment by week interaction as fixed factors; baseline stiffness WOMAC scores for the 2-item subscale as a covariate; and patient as a random factor. |
| Percentage of Participants With a >=30% and a >=50% Response in Average Evening Pain Intensity of WOMAC Question 1 in the Target Knee During the Last 5 Days of Treatment Compared With Baseline | Baseline (day -5 to day -1), Last 5 days of treatment (day 24 to day 28) | WOMAC Question 1 is the first question in the pain domain and asks patients to rate their pain in the target knee while walking on a flat surface. The possible score for each item ranges from 0 (no pain) to 100 mm (worst pain). Average pain is calculated using a MMRM which includes week, treatment, study center, and treatment by week interaction as fixed factors; baseline average evening WOMAC Question 1 score as a covariate; and patient as a random factor. Responder rate was calculated as 100 \* the value of (average WOMAC pain subscale during the last 5 days of treatment \[Days 24 to 28\]) - average WOMAC pain subscale at baseline \[the 5 days prior to randomization\])/average WOMAC pain subscale at baseline (the 5 days prior to randomization). Participants with missing responder rates were treated as nonresponders. |
| Change From Baseline to Last 5 Days of Treatment in the Average Daily WOMAC Pain Subscale Score In the Target Knee Using a Mixed Model for Repeated Measures | Baseline (day -5 to day -1), Last 5 days of treatment (day 24 to day 28) | The five items in the WOMAC Pain Subscale cover pain during walking, using stairs, in bed, sitting or lying, and standing. Daily WOMAC pain subscale score is calculated as the sum of the 5-item pain subscale scores (WOMAC) recorded at evening for a total range of 0 (no pain) to 500 (worst pain on all 5 items). Negative change from baseline scores indicate improvement in pain. MMRM includes week, treatment, study center, and treatment by week interaction as fixed factors; baseline average evening WOMAC scores for the 5-item pain subscale as a covariate; and patient as a random factor. |
| Participants' Global Assess of Treatment as Measured by the Patient Global Impression of Change (PGIC) at Weeks 2 and 4 Using a Mixed Model for Repeated Measures (MMRM) | Weeks 2 (day 15), 4 (day 29) | PGIC is a standardized self-report tool that measures the change in a participants overall status rating since the start of treatment on 7-point scale. The 7-point scale is defined as: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. The MMRM model includes week, treatment, study center, and treatment by week interaction as the fixed factors and unconstructed variance-covariance structure. |
| Change From Baseline in the Patient Global Assessment (PGA) Scores at Weeks 2 and 4 Using a Mixed Model for Repeated Measures (MMRM) | Baseline (day 1, predose), Week 2 (day 15) and Week 4 (day 29) | PGA is a simple self-report tool for measuring the overall way arthritis is affecting the patient at a particular point in time. There is 1 question and the response is provided on a visual analog scale (VAS) from 0 (very poor) to 100 (very good). The question is: Considering all the ways your arthritis affect you, how are you feeling today? Positive change from baseline scores indicate improvement. The MMRM model includes week, treatment, study center, and treatment by week interaction as the fixed factors; baseline PGA score as a covariate and unconstructed variance-covariance structure. |
| Percentage of Participants Who Are Responders Per Outcome Measures in Rheumatoid Arthritis Clinical Trials-Osteoarthritis Research Society International (OMERACT-OARSI) Criteria at Week 4 | Week 4 (day 29) | Participants are classified as 'Yes' if the following criteria are met: - \>=50% improvement from baseline and an absolute change \>=20 on a scale of 1-100 in either the pain or physical function subscale (WOMAC). or 2 of the 3 criteria as below met: - 1) \>=20% improvement from baseline and an absolute change \>=10 on a scale of 1-100 in the pain subscale (WOMAC); - 2) \>=20% improvement from baseline and an absolute change \>=10 on a scale of 1-100 in the physical function subscale (WOMAC); - 3) at least a 20% improvement from baseline and an absolute change \>=10 on a scale of 1-100 in PGA. Otherwise, 'No' The responder rate per OMERACT-OARSI criteria was analyzed using a generalized estimating equation (GEE) method, where binary variable responder rate (Yes/No) was modeled through logit link function, with treatment, center, week, and treatment\*week as explanatory factors. The unstructured working correlation structure was applied. |
| Participants With Treatment-Emergent Adverse Events | day 1 up to day 57 | An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Relationship of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes. |
| Change From Baseline (Randomization Visit) to the Week 4 Visit in the Pain Quality Assessment Scale - Revised (PQAS-R) for the Target Knee Using a Mixed Model for Repeated Measures | Baseline (day 1, predose), Treatment: Week 4 (day 29) | PQAS-R is a standardized self-report tool that measures various aspects of a participant's pain. There are 19 questions (question 19 has 2 parts) that ask the participant to rate the various aspects (intensity, sharpness, heat, cold, etc.) of his/her pain over the past week on average on a scale of 0 to 10 (0 = not \[aspect\] and 10 = the most or worst imaginable \[aspect\]). PQAS-R score at each visit is the sum of responses for the 19 questions for a total range of 0=no pain to 200=worst imaginable pain in all aspects. Negative change from baseline scores indicate improvement in stiffness. MMRM includes week, treatment, study center, and treatment by week interaction as fixed factors; baseline PQAS-R score for the 19 questions (20 parts) as a covariate; and patient as a random factor. |
Countries
United States
Participant flow
Recruitment details
978 patients with primary OA of the knee were screened for enrollment into this study. 389 patients at 41 centers in the US met entry criteria. Of the 589 patients not enrolled, 551 were excluded on the basis of inclusion/exclusion criteria, 25 patients withdrew consent, and 8 patients were lost to follow-up before the baseline visit.
Pre-assignment details
After stratification by R1150W polymorphism status: - homozygous minor allele (positive, AA), - heterozygous (positive, AG), and - homozygous common allele (negative, GG), participants were randomly assigned by interactive response technology (IRT) to receive treatment in 1 of 3 treatment groups in a 1:1:1 ratio.
Participants by arm
| Arm | Count |
|---|---|
| TV-45070 4% TV-45070 ointment in a 4% strength applied topically twice daily to the target knee during the treatment period from day 1 through day 28. | 130 |
| TV-45070 8% TV-45070 ointment in a 8% strength applied topically twice daily to the target knee during the treatment period from day 1 through day 28. | 129 |
| Placebo Placebo ointment applied topically twice daily to the target knee during the treatment period from day 1 through day 28. | 130 |
| Total | 389 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Adverse Event | 4 | 1 | 1 |
| Overall Study | Lack of Efficacy | 0 | 0 | 3 |
| Overall Study | Lost to Follow-up | 1 | 0 | 0 |
| Overall Study | Noncompliance | 0 | 0 | 1 |
| Overall Study | Protocol Violation | 4 | 2 | 3 |
| Overall Study | Withdrawal by Subject | 2 | 7 | 5 |
Baseline characteristics
| Characteristic | TV-45070 4% | Total | Placebo | TV-45070 8% |
|---|---|---|---|---|
| Age, Continuous | 60.2 years STANDARD_DEVIATION 9.17 | 59.5 years STANDARD_DEVIATION 9.44 | 59.0 years STANDARD_DEVIATION 9.65 | 59.2 years STANDARD_DEVIATION 9.52 |
| Body Mass Index | 27.992 kg/m^2 STANDARD_DEVIATION 3.08 | 28.174 kg/m^2 STANDARD_DEVIATION 3.1092 | 28.340 kg/m^2 STANDARD_DEVIATION 3.2364 | 28.190 kg/m^2 STANDARD_DEVIATION 3.0207 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 20 Participants | 74 Participants | 29 Participants | 25 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 110 Participants | 315 Participants | 101 Participants | 104 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Height | 168.41 cm STANDARD_DEVIATION 10.835 | 168.48 cm STANDARD_DEVIATION 10.095 | 167.99 cm STANDARD_DEVIATION 9.526 | 169.06 cm STANDARD_DEVIATION 9.927 |
| R1150W Polymorphism Status Heterozygous (positive, AG) | 27 Participants | 81 Participants | 26 Participants | 28 Participants |
| R1150W Polymorphism Status Homozygous common allele (negative, GG) | 101 Participants | 302 Participants | 103 Participants | 98 Participants |
| R1150W Polymorphism Status Homozygous minor allele (positive, AA) | 2 Participants | 6 Participants | 1 Participants | 3 Participants |
| Race American Indian or Alaska Native | 1 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race Asian | 14 Participants | 31 Participants | 8 Participants | 9 Participants |
| Race Black | 25 Participants | 91 Participants | 33 Participants | 33 Participants |
| Race Other | 2 Participants | 7 Participants | 1 Participants | 4 Participants |
| Race Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race White | 88 Participants | 259 Participants | 88 Participants | 83 Participants |
| Sex: Female, Male Female | 71 Participants | 228 Participants | 82 Participants | 75 Participants |
| Sex: Female, Male Male | 59 Participants | 161 Participants | 48 Participants | 54 Participants |
| Weight | 79.83 kg STANDARD_DEVIATION 14.119 | 80.33 kg STANDARD_DEVIATION 13.568 | 80.29 kg STANDARD_DEVIATION 13.633 | 80.87 kg STANDARD_DEVIATION 13.01 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 129 | 0 / 128 | 0 / 130 |
| other Total, other adverse events | 6 / 129 | 6 / 128 | 9 / 130 |
| serious Total, serious adverse events | 1 / 129 | 0 / 128 | 1 / 130 |
Outcome results
Primary
Change From Baseline to Last 5 Days of Treatment in the Average Evening Pain Intensity In the Target Knee When Walking on a Flat Surface Using a Mixed Model for Repeated Measures (MMRM)
The Western Ontario and McMasters Universities Arthritis Index \[WOMAC\] is a widely used, validated, patient-reported questionnaire used to assess pain, stiffness, and physical function in patients with OA of the knee. It consists of 24 items separated into 3 domains (pain \[5 items\], stiffness \[2 items\], and physical function \[17 items\]). WOMAC Question 1 is the first question in the pain domain and asks patients to rate their pain in the target knee while walking on a flat surface. The possible score for each item ranges from 0 (no pain) to 100 mm (worst pain). Participants record their response to WOMAC Question 1 in the study diary based on average pain upon walking since the last assessment or over the past 12 hours. Negative change from baseline scores indicate improvement in pain. MMRM includes week, treatment, study center, and treatment by week interaction as fixed factors; baseline average evening WOMAC Question 1 score as a covariate; and patient as a random factor.
Time frame: Baseline (day -5 to day -1), Last 5 days of treatment (day 24 to day 28)
Population: The full analysis set (FAS) include all patients in the intent to treat (ITT) population who receive at least 1 dose of study drug and have at least 1 post baseline efficacy assessment. Both baseline and treatment values must be available for a participant to be included.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| TV-45070 4% | Change From Baseline to Last 5 Days of Treatment in the Average Evening Pain Intensity In the Target Knee When Walking on a Flat Surface Using a Mixed Model for Repeated Measures (MMRM) | -20.56 units on a scale | Standard Error 1.937 |
| TV-45070 8% | Change From Baseline to Last 5 Days of Treatment in the Average Evening Pain Intensity In the Target Knee When Walking on a Flat Surface Using a Mixed Model for Repeated Measures (MMRM) | -23.08 units on a scale | Standard Error 1.923 |
| Placebo | Change From Baseline to Last 5 Days of Treatment in the Average Evening Pain Intensity In the Target Knee When Walking on a Flat Surface Using a Mixed Model for Repeated Measures (MMRM) | -24.82 units on a scale | Standard Error 1.928 |
Comparison: LSM = least square meanp-value: 0.121395% CI: [-1.13, 9.66]mixed model for repeated measures
Comparison: LSM = least square meanp-value: 0.523195% CI: [-3.62, 7.11]mixed model for repeated measures
Secondary
Change From Baseline in the Patient Global Assessment (PGA) Scores at Weeks 2 and 4 Using a Mixed Model for Repeated Measures (MMRM)
PGA is a simple self-report tool for measuring the overall way arthritis is affecting the patient at a particular point in time. There is 1 question and the response is provided on a visual analog scale (VAS) from 0 (very poor) to 100 (very good). The question is: Considering all the ways your arthritis affect you, how are you feeling today? Positive change from baseline scores indicate improvement. The MMRM model includes week, treatment, study center, and treatment by week interaction as the fixed factors; baseline PGA score as a covariate and unconstructed variance-covariance structure.
Time frame: Baseline (day 1, predose), Week 2 (day 15) and Week 4 (day 29)
Population: Full analysis set of participants with data at the timepoints.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| TV-45070 4% | Change From Baseline in the Patient Global Assessment (PGA) Scores at Weeks 2 and 4 Using a Mixed Model for Repeated Measures (MMRM) | Week 2 | 4.87 units on a scale | Standard Error 1.819 |
| TV-45070 4% | Change From Baseline in the Patient Global Assessment (PGA) Scores at Weeks 2 and 4 Using a Mixed Model for Repeated Measures (MMRM) | Week 4 | 5.44 units on a scale | Standard Error 1.949 |
| TV-45070 8% | Change From Baseline in the Patient Global Assessment (PGA) Scores at Weeks 2 and 4 Using a Mixed Model for Repeated Measures (MMRM) | Week 4 | 6.35 units on a scale | Standard Error 1.935 |
| TV-45070 8% | Change From Baseline in the Patient Global Assessment (PGA) Scores at Weeks 2 and 4 Using a Mixed Model for Repeated Measures (MMRM) | Week 2 | 3.51 units on a scale | Standard Error 1.808 |
| Placebo | Change From Baseline in the Patient Global Assessment (PGA) Scores at Weeks 2 and 4 Using a Mixed Model for Repeated Measures (MMRM) | Week 2 | 2.10 units on a scale | Standard Error 1.85 |
| Placebo | Change From Baseline in the Patient Global Assessment (PGA) Scores at Weeks 2 and 4 Using a Mixed Model for Repeated Measures (MMRM) | Week 4 | 4.62 units on a scale | Standard Error 1.973 |
Comparison: Week 2p-value: 0.290695% CI: [-2.377, 7.916]mixed model for repeated measures
Comparison: Week 2p-value: 0.589295% CI: [-3.707, 6.518]mixed model for repeated measures
Comparison: Week 4p-value: 0.769995% CI: [-4.678, 6.315]mixed model for repeated measures
Comparison: Week 4p-value: 0.53295% CI: [-3.721, 7.193]mixed model for repeated measures
Secondary
Change From Baseline (Randomization Visit) to the Week 4 Visit in the Pain Quality Assessment Scale - Revised (PQAS-R) for the Target Knee Using a Mixed Model for Repeated Measures
PQAS-R is a standardized self-report tool that measures various aspects of a participant's pain. There are 19 questions (question 19 has 2 parts) that ask the participant to rate the various aspects (intensity, sharpness, heat, cold, etc.) of his/her pain over the past week on average on a scale of 0 to 10 (0 = not \[aspect\] and 10 = the most or worst imaginable \[aspect\]). PQAS-R score at each visit is the sum of responses for the 19 questions for a total range of 0=no pain to 200=worst imaginable pain in all aspects. Negative change from baseline scores indicate improvement in stiffness. MMRM includes week, treatment, study center, and treatment by week interaction as fixed factors; baseline PQAS-R score for the 19 questions (20 parts) as a covariate; and patient as a random factor.
Time frame: Baseline (day 1, predose), Treatment: Week 4 (day 29)
Population: Full analysis set. If any of the 19 questions is missing, the PQAS-R total score will not be calculated for a given visit. If the entire questionnaire is not done at a scheduled time point, it will be considered missing and will not be imputed.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| TV-45070 4% | Change From Baseline (Randomization Visit) to the Week 4 Visit in the Pain Quality Assessment Scale - Revised (PQAS-R) for the Target Knee Using a Mixed Model for Repeated Measures | -39.22 units on a scale | Standard Error 3.489 |
| TV-45070 8% | Change From Baseline (Randomization Visit) to the Week 4 Visit in the Pain Quality Assessment Scale - Revised (PQAS-R) for the Target Knee Using a Mixed Model for Repeated Measures | -40.65 units on a scale | Standard Error 3.453 |
| Placebo | Change From Baseline (Randomization Visit) to the Week 4 Visit in the Pain Quality Assessment Scale - Revised (PQAS-R) for the Target Knee Using a Mixed Model for Repeated Measures | -43.16 units on a scale | Standard Error 3.529 |
p-value: 0.431695% CI: [-5.9, 13.79]mixed model for repeated measures
p-value: 0.612695% CI: [-7.24, 12.26]mixed model for repeated measures
Secondary
Change From Baseline (Randomization Visit) to the Week 4 Visit in the WOMAC Physical Function Subscale Score for the Target Knee Using a Mixed Model for Repeated Measures
The seventeen items in the WOMAC physical function subscale cover stair use, rising from sitting, standing, bending, walking, getting in / out of a car, shopping, putting on / taking off socks, rising from bed, lying in bed, getting in / out of bath, sitting, getting on / off toilet, heavy household duties, light household duties. WOMAC physical function subscale score is calculated as the sum of the 17-item physical function subscale scores (WOMAC) for a total range of 0 (no pain) to 1700 (worst pain on all 17 items). Negative change from baseline scores indicate improvement in pain. MMRM includes week, treatment, study center, and treatment by week interaction as fixed factors; baseline physical function WOMAC scores for the 17-item subscale as a covariate; and patient as a random factor.
Time frame: Baseline (day 1, predose), Treatment: Week 4 (day 29)
Population: Full analysis set. Both baseline and treatment values must be available for a participant to be included. For physical function subscale, if more than 3 items are missing the subscale total will not be calculated; otherwise the missing value will be replaced by the average of the non-missing values in the subscale.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| TV-45070 4% | Change From Baseline (Randomization Visit) to the Week 4 Visit in the WOMAC Physical Function Subscale Score for the Target Knee Using a Mixed Model for Repeated Measures | -372.88 units on a scale | Standard Error 35.169 |
| TV-45070 8% | Change From Baseline (Randomization Visit) to the Week 4 Visit in the WOMAC Physical Function Subscale Score for the Target Knee Using a Mixed Model for Repeated Measures | -446.79 units on a scale | Standard Error 34.812 |
| Placebo | Change From Baseline (Randomization Visit) to the Week 4 Visit in the WOMAC Physical Function Subscale Score for the Target Knee Using a Mixed Model for Repeated Measures | -396.39 units on a scale | Standard Error 35.59 |
p-value: 0.64295% CI: [-75.83, 122.84]mixed model for repeated measures
p-value: 0.314195% CI: [-148.72, 47.92]mixed model for repeated measures
Secondary
Change From Baseline (Randomization Visit) to the Week 4 Visit in the WOMAC Stiffness Subscale Score for the Target Knee Using a Mixed Model for Repeated Measures
The two items in the WOMAC stiffness subscale cover stiffness after first waking and later in the day. WOMAC stiffness subscale score is calculated as the sum of the 2-item stiffness subscale scores (WOMAC) for a total range of 0 (no stiffness) to 200 (worst stiffness on both items). Negative change from baseline scores indicate improvement in stiffness. MMRM includes week, treatment, study center, and treatment by week interaction as fixed factors; baseline stiffness WOMAC scores for the 2-item subscale as a covariate; and patient as a random factor.
Time frame: Baseline (day 1, predose), Treatment: Week 4 (day 29)
Population: Full analysis set. Both baseline and treatment values must be available for a participant to be included. For stiffness subscale, if both items are missing, the subscale total will not be calculated; otherwise the missing value will be replaced with the non-missing one in the subscale.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| TV-45070 4% | Change From Baseline (Randomization Visit) to the Week 4 Visit in the WOMAC Stiffness Subscale Score for the Target Knee Using a Mixed Model for Repeated Measures | -45.85 units on a scale | Standard Error 4.414 |
| TV-45070 8% | Change From Baseline (Randomization Visit) to the Week 4 Visit in the WOMAC Stiffness Subscale Score for the Target Knee Using a Mixed Model for Repeated Measures | -52.49 units on a scale | Standard Error 4.358 |
| Placebo | Change From Baseline (Randomization Visit) to the Week 4 Visit in the WOMAC Stiffness Subscale Score for the Target Knee Using a Mixed Model for Repeated Measures | -49.01 units on a scale | Standard Error 4.455 |
p-value: 0.618495% CI: [-9.31, 15.63]mixed model for repeated measures
p-value: 0.577595% CI: [-15.78, 8.81]mixed model for repeated measures
Secondary
Change From Baseline to Last 5 Days of Treatment in the Average Daily WOMAC Pain Subscale Score In the Target Knee Using a Mixed Model for Repeated Measures
The five items in the WOMAC Pain Subscale cover pain during walking, using stairs, in bed, sitting or lying, and standing. Daily WOMAC pain subscale score is calculated as the sum of the 5-item pain subscale scores (WOMAC) recorded at evening for a total range of 0 (no pain) to 500 (worst pain on all 5 items). Negative change from baseline scores indicate improvement in pain. MMRM includes week, treatment, study center, and treatment by week interaction as fixed factors; baseline average evening WOMAC scores for the 5-item pain subscale as a covariate; and patient as a random factor.
Time frame: Baseline (day -5 to day -1), Last 5 days of treatment (day 24 to day 28)
Population: Full analysis set. Both baseline and treatment values must be available for a participant to be included. For pain subscale, if more than 1 item is missing, the subscale total will not be calculated; otherwise the missing value will be replaced by average of the non-missing values in the subscale.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| TV-45070 4% | Change From Baseline to Last 5 Days of Treatment in the Average Daily WOMAC Pain Subscale Score In the Target Knee Using a Mixed Model for Repeated Measures | -99.67 units on a scale | Standard Error 9.365 |
| TV-45070 8% | Change From Baseline to Last 5 Days of Treatment in the Average Daily WOMAC Pain Subscale Score In the Target Knee Using a Mixed Model for Repeated Measures | -108.52 units on a scale | Standard Error 9.3 |
| Placebo | Change From Baseline to Last 5 Days of Treatment in the Average Daily WOMAC Pain Subscale Score In the Target Knee Using a Mixed Model for Repeated Measures | -117.53 units on a scale | Standard Error 9.329 |
Comparison: LSM = least square meanp-value: 0.179595% CI: [-8.26, 43.98]mixed model for repeated measures
Comparison: LSM = least square meanp-value: 0.495695% CI: [-16.95, 34.96]mixed model for repeated measures
Secondary
Change From Baseline to Last 5 Days of Treatment in the Average Morning Pain Intensity In the Target Knee When Walking on a Flat Surface Using a Mixed Model for Repeated Measures (MMRM)
The Western Ontario and McMasters Universities Arthritis Index \[WOMAC\] is a widely used, validated, patient-reported questionnaire used to assess pain, stiffness, and physical function in patients with OA of the knee. It consists of 24 items separated into 3 domains (pain \[5 items\], stiffness \[2 items\], and physical function \[17 items\]). The possible score for each item ranges from 0 (no pain) to 100 mm (worst pain). WOMAC Question 1 is the first question in the pain domain and asks patients to rate their pain in the target knee while walking on a flat surface. Participants record their response to WOMAC Question 1 in the study diary based on average pain upon walking since the last assessment or over the past 12 hours. Negative change from baseline scores indicate improvement in pain. MMRM includes week, treatment, study center, and treatment by week interaction as fixed factors; baseline average morning WOMAC Question 1 score as a covariate; and patient as a random factor.
Time frame: Baseline (day -5 to day -1), Last 5 days of treatment (day 24 to day 28)
Population: The full analysis set (FAS) include all patients in the intent to treat (ITT) population who receive at least 1 dose of study drug and have at least 1 post baseline efficacy assessment. Both baseline and treatment values must be available for a participant to be included.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| TV-45070 4% | Change From Baseline to Last 5 Days of Treatment in the Average Morning Pain Intensity In the Target Knee When Walking on a Flat Surface Using a Mixed Model for Repeated Measures (MMRM) | -19.84 units on a scale | Standard Error 1.968 |
| TV-45070 8% | Change From Baseline to Last 5 Days of Treatment in the Average Morning Pain Intensity In the Target Knee When Walking on a Flat Surface Using a Mixed Model for Repeated Measures (MMRM) | -21.39 units on a scale | Standard Error 1.955 |
| Placebo | Change From Baseline to Last 5 Days of Treatment in the Average Morning Pain Intensity In the Target Knee When Walking on a Flat Surface Using a Mixed Model for Repeated Measures (MMRM) | -23.45 units on a scale | Standard Error 1.956 |
p-value: 0.196395% CI: [-1.87, 9.08]mixed model for repeated measures
p-value: 0.458495% CI: [-3.39, 7.5]mixed model for repeated measures
Secondary
Participants' Global Assess of Treatment as Measured by the Patient Global Impression of Change (PGIC) at Weeks 2 and 4 Using a Mixed Model for Repeated Measures (MMRM)
PGIC is a standardized self-report tool that measures the change in a participants overall status rating since the start of treatment on 7-point scale. The 7-point scale is defined as: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. The MMRM model includes week, treatment, study center, and treatment by week interaction as the fixed factors and unconstructed variance-covariance structure.
Time frame: Weeks 2 (day 15), 4 (day 29)
Population: Full analysis set of participants with data at the timepoint.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| TV-45070 4% | Participants' Global Assess of Treatment as Measured by the Patient Global Impression of Change (PGIC) at Weeks 2 and 4 Using a Mixed Model for Repeated Measures (MMRM) | Week 2 | 2.87 units on a scale | Standard Error 0.086 |
| TV-45070 4% | Participants' Global Assess of Treatment as Measured by the Patient Global Impression of Change (PGIC) at Weeks 2 and 4 Using a Mixed Model for Repeated Measures (MMRM) | Week 4 | 2.81 units on a scale | Standard Error 0.096 |
| TV-45070 8% | Participants' Global Assess of Treatment as Measured by the Patient Global Impression of Change (PGIC) at Weeks 2 and 4 Using a Mixed Model for Repeated Measures (MMRM) | Week 2 | 2.90 units on a scale | Standard Error 0.086 |
| TV-45070 8% | Participants' Global Assess of Treatment as Measured by the Patient Global Impression of Change (PGIC) at Weeks 2 and 4 Using a Mixed Model for Repeated Measures (MMRM) | Week 4 | 2.66 units on a scale | Standard Error 0.095 |
| Placebo | Participants' Global Assess of Treatment as Measured by the Patient Global Impression of Change (PGIC) at Weeks 2 and 4 Using a Mixed Model for Repeated Measures (MMRM) | Week 2 | 2.86 units on a scale | Standard Error 0.088 |
| Placebo | Participants' Global Assess of Treatment as Measured by the Patient Global Impression of Change (PGIC) at Weeks 2 and 4 Using a Mixed Model for Repeated Measures (MMRM) | Week 4 | 2.60 units on a scale | Standard Error 0.097 |
Comparison: Week 2p-value: 0.920895% CI: [-0.232, 0.257]mixed model for repeated measures
Comparison: Week 2p-value: 0.734495% CI: [-0.2, 0.284]mixed model for repeated measures
Comparison: Week 4p-value: 0.119995% CI: [-0.056, 0.486]mixed model for repeated measures
Comparison: Week 4p-value: 0.635795% CI: [-0.204, 0.334]mixed model for repeated measures
Secondary
Participants With Treatment-Emergent Adverse Events
An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Relationship of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.
Time frame: day 1 up to day 57
Population: Safety analysis population. The safety population includes all randomized participants who receive at least one dose of study medication. In this population, treatment was assigned based upon the treatment participants actually receive regardless of the treatment to which they were randomized.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| TV-45070 4% | Participants With Treatment-Emergent Adverse Events | Serious TEAE | 1 Participants |
| TV-45070 4% | Participants With Treatment-Emergent Adverse Events | Death | 0 Participants |
| TV-45070 4% | Participants With Treatment-Emergent Adverse Events | Any treatment-emergent adverse event | 43 Participants |
| TV-45070 4% | Participants With Treatment-Emergent Adverse Events | Treatment-related TEAE | 12 Participants |
| TV-45070 4% | Participants With Treatment-Emergent Adverse Events | Withdrawn from treatment due to TEAE | 3 Participants |
| TV-45070 8% | Participants With Treatment-Emergent Adverse Events | Death | 0 Participants |
| TV-45070 8% | Participants With Treatment-Emergent Adverse Events | Any treatment-emergent adverse event | 37 Participants |
| TV-45070 8% | Participants With Treatment-Emergent Adverse Events | Treatment-related TEAE | 10 Participants |
| TV-45070 8% | Participants With Treatment-Emergent Adverse Events | Serious TEAE | 0 Participants |
| TV-45070 8% | Participants With Treatment-Emergent Adverse Events | Withdrawn from treatment due to TEAE | 2 Participants |
| Placebo | Participants With Treatment-Emergent Adverse Events | Withdrawn from treatment due to TEAE | 2 Participants |
| Placebo | Participants With Treatment-Emergent Adverse Events | Serious TEAE | 1 Participants |
| Placebo | Participants With Treatment-Emergent Adverse Events | Any treatment-emergent adverse event | 47 Participants |
| Placebo | Participants With Treatment-Emergent Adverse Events | Death | 0 Participants |
| Placebo | Participants With Treatment-Emergent Adverse Events | Treatment-related TEAE | 20 Participants |
Secondary
Percentage of Participants Who Are Responders Per Outcome Measures in Rheumatoid Arthritis Clinical Trials-Osteoarthritis Research Society International (OMERACT-OARSI) Criteria at Week 4
Participants are classified as 'Yes' if the following criteria are met: - \>=50% improvement from baseline and an absolute change \>=20 on a scale of 1-100 in either the pain or physical function subscale (WOMAC). or 2 of the 3 criteria as below met: - 1) \>=20% improvement from baseline and an absolute change \>=10 on a scale of 1-100 in the pain subscale (WOMAC); - 2) \>=20% improvement from baseline and an absolute change \>=10 on a scale of 1-100 in the physical function subscale (WOMAC); - 3) at least a 20% improvement from baseline and an absolute change \>=10 on a scale of 1-100 in PGA. Otherwise, 'No' The responder rate per OMERACT-OARSI criteria was analyzed using a generalized estimating equation (GEE) method, where binary variable responder rate (Yes/No) was modeled through logit link function, with treatment, center, week, and treatment\*week as explanatory factors. The unstructured working correlation structure was applied.
Time frame: Week 4 (day 29)
Population: Full analysis set
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| TV-45070 4% | Percentage of Participants Who Are Responders Per Outcome Measures in Rheumatoid Arthritis Clinical Trials-Osteoarthritis Research Society International (OMERACT-OARSI) Criteria at Week 4 | Responder - No | 46.5 percentage of participants |
| TV-45070 4% | Percentage of Participants Who Are Responders Per Outcome Measures in Rheumatoid Arthritis Clinical Trials-Osteoarthritis Research Society International (OMERACT-OARSI) Criteria at Week 4 | Responder - Yes | 47.3 percentage of participants |
| TV-45070 4% | Percentage of Participants Who Are Responders Per Outcome Measures in Rheumatoid Arthritis Clinical Trials-Osteoarthritis Research Society International (OMERACT-OARSI) Criteria at Week 4 | Missing | 6.2 percentage of participants |
| TV-45070 8% | Percentage of Participants Who Are Responders Per Outcome Measures in Rheumatoid Arthritis Clinical Trials-Osteoarthritis Research Society International (OMERACT-OARSI) Criteria at Week 4 | Responder - No | 36.7 percentage of participants |
| TV-45070 8% | Percentage of Participants Who Are Responders Per Outcome Measures in Rheumatoid Arthritis Clinical Trials-Osteoarthritis Research Society International (OMERACT-OARSI) Criteria at Week 4 | Responder - Yes | 59.4 percentage of participants |
| TV-45070 8% | Percentage of Participants Who Are Responders Per Outcome Measures in Rheumatoid Arthritis Clinical Trials-Osteoarthritis Research Society International (OMERACT-OARSI) Criteria at Week 4 | Missing | 3.9 percentage of participants |
| Placebo | Percentage of Participants Who Are Responders Per Outcome Measures in Rheumatoid Arthritis Clinical Trials-Osteoarthritis Research Society International (OMERACT-OARSI) Criteria at Week 4 | Responder - Yes | 51.5 percentage of participants |
| Placebo | Percentage of Participants Who Are Responders Per Outcome Measures in Rheumatoid Arthritis Clinical Trials-Osteoarthritis Research Society International (OMERACT-OARSI) Criteria at Week 4 | Missing | 7.7 percentage of participants |
| Placebo | Percentage of Participants Who Are Responders Per Outcome Measures in Rheumatoid Arthritis Clinical Trials-Osteoarthritis Research Society International (OMERACT-OARSI) Criteria at Week 4 | Responder - No | 40.8 percentage of participants |
Comparison: For the responder analyses, participants with missing values were deemed non-responders. Analysis performed using a generalized estimating equation (GEE) method where binary variable responder rate (Yes/No) was modeled through logit link function, with treatment, center, week, and treatment\*week as explanatory factors. The unstructured working correlation structure was applied.p-value: 0.535895% CI: [0.501, 1.433]generalized estimating equation (GEE)
Comparison: For the responder analyses, participants with missing values were deemed non-responders. Analysis performed using a generalized estimating equation (GEE) method where binary variable responder rate (Yes/No) was modeled through logit link function, with treatment, center, week, and treatment\*week as explanatory factors. The unstructured working correlation structure was applied.p-value: 0.153295% CI: [0.87, 2.423]generalized estimating equation (GEE)
Secondary
Percentage of Participants With a >=30% and a >=50% Response in Average Evening Pain Intensity of WOMAC Question 1 in the Target Knee During the Last 5 Days of Treatment Compared With Baseline
WOMAC Question 1 is the first question in the pain domain and asks patients to rate their pain in the target knee while walking on a flat surface. The possible score for each item ranges from 0 (no pain) to 100 mm (worst pain). Average pain is calculated using a MMRM which includes week, treatment, study center, and treatment by week interaction as fixed factors; baseline average evening WOMAC Question 1 score as a covariate; and patient as a random factor. Responder rate was calculated as 100 \* the value of (average WOMAC pain subscale during the last 5 days of treatment \[Days 24 to 28\]) - average WOMAC pain subscale at baseline \[the 5 days prior to randomization\])/average WOMAC pain subscale at baseline (the 5 days prior to randomization). Participants with missing responder rates were treated as nonresponders.
Time frame: Baseline (day -5 to day -1), Last 5 days of treatment (day 24 to day 28)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| TV-45070 4% | Percentage of Participants With a >=30% and a >=50% Response in Average Evening Pain Intensity of WOMAC Question 1 in the Target Knee During the Last 5 Days of Treatment Compared With Baseline | >=50% responder rate | 23.3 percentage of participants |
| TV-45070 4% | Percentage of Participants With a >=30% and a >=50% Response in Average Evening Pain Intensity of WOMAC Question 1 in the Target Knee During the Last 5 Days of Treatment Compared With Baseline | <50% responder rate | 70.5 percentage of participants |
| TV-45070 4% | Percentage of Participants With a >=30% and a >=50% Response in Average Evening Pain Intensity of WOMAC Question 1 in the Target Knee During the Last 5 Days of Treatment Compared With Baseline | >=30% responder rate | 45.0 percentage of participants |
| TV-45070 4% | Percentage of Participants With a >=30% and a >=50% Response in Average Evening Pain Intensity of WOMAC Question 1 in the Target Knee During the Last 5 Days of Treatment Compared With Baseline | <30% responder rate | 48.8 percentage of participants |
| TV-45070 8% | Percentage of Participants With a >=30% and a >=50% Response in Average Evening Pain Intensity of WOMAC Question 1 in the Target Knee During the Last 5 Days of Treatment Compared With Baseline | <30% responder rate | 52.3 percentage of participants |
| TV-45070 8% | Percentage of Participants With a >=30% and a >=50% Response in Average Evening Pain Intensity of WOMAC Question 1 in the Target Knee During the Last 5 Days of Treatment Compared With Baseline | >=50% responder rate | 33.6 percentage of participants |
| TV-45070 8% | Percentage of Participants With a >=30% and a >=50% Response in Average Evening Pain Intensity of WOMAC Question 1 in the Target Knee During the Last 5 Days of Treatment Compared With Baseline | >=30% responder rate | 43.8 percentage of participants |
| TV-45070 8% | Percentage of Participants With a >=30% and a >=50% Response in Average Evening Pain Intensity of WOMAC Question 1 in the Target Knee During the Last 5 Days of Treatment Compared With Baseline | <50% responder rate | 62.5 percentage of participants |
| Placebo | Percentage of Participants With a >=30% and a >=50% Response in Average Evening Pain Intensity of WOMAC Question 1 in the Target Knee During the Last 5 Days of Treatment Compared With Baseline | <30% responder rate | 45.4 percentage of participants |
| Placebo | Percentage of Participants With a >=30% and a >=50% Response in Average Evening Pain Intensity of WOMAC Question 1 in the Target Knee During the Last 5 Days of Treatment Compared With Baseline | <50% responder rate | 60.8 percentage of participants |
| Placebo | Percentage of Participants With a >=30% and a >=50% Response in Average Evening Pain Intensity of WOMAC Question 1 in the Target Knee During the Last 5 Days of Treatment Compared With Baseline | >=30% responder rate | 46.9 percentage of participants |
| Placebo | Percentage of Participants With a >=30% and a >=50% Response in Average Evening Pain Intensity of WOMAC Question 1 in the Target Knee During the Last 5 Days of Treatment Compared With Baseline | >=50% responder rate | 31.5 percentage of participants |
Comparison: \>=50% responder ratep-value: 0.101195% CI: [0.345, 1.099]mixed model for repeated measures
Comparison: \>=50% responder ratep-value: 0.8495% CI: [0.615, 1.819]mixed model for repeated measures
Comparison: \>=30% responder ratep-value: 0.660795% CI: [0.531, 1.494]mixed model for repeated measures
Comparison: \>=30% responder ratep-value: 0.577795% CI: [0.52, 1.441]mixed model for repeated measures